Epidermal Growth Factor Enhances Orthovanadate-Induced Contraction via Src and Myosin Phosphatase Target Subunit 1 in Rat Vascular Smooth Muscle


Inhibition of protein tyrosine phosphatase by orthovanadate induces vasoconstriction, which is mediated by the Rho kinase-dependent inactivation of myosin light chain phosphatase (MLCP) via signaling downstream of Src-induced activation of the epidermal growth factor (EGF) receptor. The present study investigated the potential role of EGF in orthovanadate (OVA)-dependent vaso-constriction. OVA-induced aortic contraction significantly increased in the presence of EGF, and was abolished by inhibitors of Rho kinase (Y27632), extracellular signal-regulated kinase 1 and 2 (Erk1/2) (FR180204), Erk1/2 kinase (PD98059), EGF receptor (AG1478), and Src (PP2). Treatment of the rat endothelium-denuded thoracic aorta with either EGF or OVA augmented the phosphorylation of myosin phosphatase target subunit 1 (MYPT1) at Thr-853 and of the EGF receptor at Tyr-1173. The phosphorylation of MYPT1 was further increased by co-stimulation with EGF and OVA. EGF receptor phosphorylation at Tyr-845 was also increased by EGF or OVA; this effect was augmented by co-stimulation with EGF and OVA, and was abolished by Src inhibition. In addition, Erk1/2 was phosphorylated by EGF or by co-treatment with EGF and OVA; this was abolished by an EGF receptor inhibitor, but not by Src inhibition. These results suggested that OVA-induced EGF-related contraction was mediated by the Rho kinase-dependent inactivation of MLCP via two different signaling cascades: Src-dependent phosphorylation of the EGF receptor at Tyr-845 and EGF-dependent phosphorylation of Erk1/2.

Share and Cite:

Sasahara, T. , Ohkura, N. , Shin, M. , Onodera, A. and Yayama, K. (2015) Epidermal Growth Factor Enhances Orthovanadate-Induced Contraction via Src and Myosin Phosphatase Target Subunit 1 in Rat Vascular Smooth Muscle. Pharmacology & Pharmacy, 6, 329-340. doi: 10.4236/pp.2015.67035.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] Kamm, K.E. and Stull, J.T. (1985) The Function of Myosin and Myosin Light Chain Kinase Phosphorylation in Smooth Muscle. Annual Review of Pharmacology and Toxicology, 25, 593-620.
[2] Lin, G., Fandel, T.M., Shindel, A.W., Wang, G., Banie, L., Ning, H., Lue, T.F. and Lin, C.S. (2011) Modulation of Smooth Muscle Tonus in the Lower Urinary Tract: Interplay of Myosin Light-Chain Kinase (MLCK) and MLC Phosphatase (MLCP). BJU International, 108, E66-E70.
[3] Arimura, T., Suematsu, N., Zhou, Y.B., Nishimura, J., Satoh, S., Takeshita, A., Kanaide, H. and Kimura, A. (2001) Identification, Characterization, and Functional Analysis of Heart-Specific Myosin Light Chain Phosphatase Small Subunit. The Journal of Biological Chemistry, 276, 6073-6082.
[4] Somlyo, A.P. and Somlyo, A.V. (2003) Ca2+ Sensitivity of Smooth Muscle and Nonmuscle Myosin II: Modulated by G Proteins, Kinases, and Myosin Phosphatase. Physiological Reviews, 83, 1325-1358.
[5] Sward, K., Mita, M., Wilson, D.P., Deng, J.T., Susnjar, M. and Walsh, M.P. (2003) The Role of RhoA and Rho-Associated Kinase in Vascular Smooth Muscle Contraction. Current Hypertension Reports, 5, 66-72.
[6] Tiganis, T. and Bennett, A.M. (2007) Protein Tyrosine Phosphatase Function: The Substrate Perspective. Biochemical Journal, 402, 1-15.
[7] Swarup, G., Cohen, S. and Garbers, D.L. (1982) Inhibition of Membrane Phosphotyrosyl-Protein Phosphatase Activity by Vanadate. Biochemical and Biophysical Research Communications, 107, 1104-1109.
[8] Cantley Jr., L.C. Josephson, L., Warner, R., Yanagisawa, M., Lechene, C. and Guidotti, G. (1977) Vanadate Is a Potent (Na,K)-ATPase Inhibitor Found in ATP Derived from Muscle. The Journal of Biological Chemistry, 252, 7421-7423.
[9] Chen, Y. and Chan, T.M. (1993) Orthovanadate and 2,3-Dimethoxy-1,4-naphthoquinone Augment Growth Factor-Induced Cell Proliferation and c-fos Gene Expression in 3T3-L1 Cells. Archives of Biochemistry and Biophysics, 305, 9-16.
[10] Mehdi, M.Z., Pandey, S.K., Theberge, J.F. and Srivastava, A.K. (2006) Insulin Signal Mimicry as a Mechanism for the Insulin-Like Effects of Vanadium. Cell Biochemistry and Biophysics, 44, 73-81.
[11] Morita, A., Yamamoto, S., Wang, B., Tanaka, K., Suzuki, N., Aoki, S., Ito, A., Nanao, T., Ohya, S., Yoshino, M., Zhu, J., Enomoto, A., Matsumoto, Y., Funatsu, O., Hosoi, Y. and Ikekita, M. (2010) Sodium Orthovanadate Inhibits p53-Mediated Apoptosis. Cancer Research, 70, 257-265.
[12] Wozniak, K. and Blasiak, J. (2004) Vanadyl Sulfate Can Differentially Damage DNA in Human Lymphocytes and HeLa Cells. Archives of Toxicology, 78, 7-15.
[13] Sabbioni, E., Pozzi, G., Pintar, A., Casella, L. and Garattini, S. (1991) Cellular Retention, Cytotoxicity and Morphological Transformation by Vanadium(IV) and Vanadium(V) in BALB/3T3 Cell Lines. Carcinogenesis, 12, 47-52.
[14] Soeda, S., Shimada, T., Koyanagi, S., Yokomatsu, T., Murano, T., Shibuya, S. and Shimeno, H. (2002) An Attempt to Promote Neo-Vascularization by Employing a Newly Synthesized Inhibitor of Protein Tyrosine Phosphatase. FEBS Letters, 524, 54-58.
[15] Carr, A.N., Davis, M.G., Eby-Wilkens, E., Howard, B.W., Towne, B.A., Dufresne, T.E. and Peters, K.G. (2004) Tyrosine Phosphatase Inhibition Augments Collateral Blood Flow in a Rat Model of Peripheral Vascular Disease. AJP: Heart and Circulatory Physiology, 287, H268-H276.
[16] Natarajan, V., Scribner, W.M. and Vepa, S. (1997) Phosphatase Inhibitors Potentiate 4-Hydroxynonenal-Induced Phospholipase D Activation in Vascular Endothelial Cells. American Journal of Respiratory Cell and Molecular Biology, 17, 251-259.
[17] Yuan, Y., Meng, F.Y., Huang, Q., Hawker, J. and Wu, H.M. (1998) Tyrosine Phosphorylation of Paxillin/pp125FAK and Microvascular Endothelial Barrier Function. American Journal of Physiology, 275, H84-H93.
[18] Garcia, J.G., Schaphorst, K.L., Verin, A.D., Vepa, S., Patterson, C.E. and Natarajan, V. (1985) Diperoxovanadate Alters Endothelial Cell Focal Contacts and Barrier Function: Role of Tyrosine Phosphorylation. Journal of Applied Physiology, 89, 2333-2343.
[19] Suzuki, E., Nagata, D., Yoshizumi, M., Kakoki, M., Goto, A., Omata, M. and Hirata, Y. (2000) Reentry into the Cell Cycle of Contact-Inhibited Vascular Endothelial Cells by a Phosphatase Inhibitor. Possible Involvement of Extracellular Signal-Regulated Kinase and Phosphatidylinositol 3-Kinase. The Journal of Biological Chemistry, 275, 3637-3644.
[20] Shimizu, H., Takayama, H., Lee, J.D., Satake, K., Taniguchi, T., Yamamura, H. and Nakamura, T. (1994) Effects of Vanadate on Prostacyclin and Endothelin-1 Production and Protein-Tyrosine Phosphorylation in Human Endothelial Cells. Thrombosis and Haemostasis, 72, 973-978.
[21] Helgadottir, A., Halldorsson, H., Magnusdottir, K., Kjeld, M. and Thorgeirsson, G. (1997) A Role for Tyrosine Phosphorylation in Generation of Inositol Phosphates and Prostacyclin Production in Endothelial Cells. Arteriosclerosis, Thrombosis, and Vascular Biology, 17, 287-294.
[22] Hellermann, G.R., Flam, B.R., Eichler, D.C. and Solomonson, L.P. (2000) Stimulation of Receptor-Mediated Nitric Oxide Production by Vanadate. Arteriosclerosis, Thrombosis, and Vascular Biology, 20, 2045-2050.
[23] Nakaike, R., Shimokawa, H., Owada, M.K., Tokunaga, O., Yasutake, H., Kishimoto, T., Imada, C., Shiraishi, T., Egashira, K. and Takeshita, A. (1996) Vanadate Causes Synthesis of Endothelium-Derived NO via Pertussis Toxin-Sensitive G Protein in Pigs. American Journal of Physiology, 271, H296-H302.
[24] Di Salvo, J., Semenchuk, L.A. and Lauer, J. (1993) Vanadate-Induced Contraction of Smooth Muscle and Enhanced Protein Tyrosine Phosphorylation. Archives of Biochemistry and Biophysics, 304, 386-391.
[25] Nayler, R.A. and Sparrow, M.P. (1983) Mechanism of Vanadate-Induced Contraction of Airways Smooth Muscle of the Guinea-Pig. British Journal of Pharmacology, 80, 163-172.
[26] Alcon, S., Camello, P.J., Garcia, L.J. and Pozo, M.J. (2000) Activation of Tyrosine Kinase Pathway by Vanadate in Gallbladder Smooth Muscle. Biochemical Pharmacology, 59, 1077-1089.
[27] Laniyonu, A., Saifeddine, M., Ahmad, S. and Hollenberg, M.D. (1994) Regulation of Vascular and Gastric Smooth Muscle Contractility by Pervanadate. British Journal of Pharmacology, 113, 403-410.
[28] Boulven, I., Robin, P., Desmyter, C., Harbon, S. and Leiber, D. (2002) Differential Involvement of Src Family Kinases in Pervanadate-Mediated Responses in Rat Myometrial Cells. Cellular Signalling, 14, 341-349.
[29] Mori, M. and Tsushima, H. (2004) Vanadate Activates Rho A Translocation in Association with Contracting Effects in Ileal Longitudinal Smooth Muscle of Guinea Pig. Journal of Pharmacological Sciences, 95, 443-451.
[30] Yayama, K., Sasahara, T., Ohba, H., Funasaka, A. and Okamoto, H. (2014) Orthovanadate-Induced Vasocontraction Is Mediated by the Activation of Rho-Kinase through Src-Dependent Transactivation of Epidermal Growth Factor Receptor. Pharmacology Research & Perspectives, 2, Article ID: e00039.
[31] Sasahara, T., Ohkura, N., Kobe, A. and Yayama, K. (2015) Epidermal Growth Factor Induces Ca2+ Sensitization through Rho-Kinase-Dependent Phosphorylation of Myosin Phosphatase Target Subunit 1 in Vascular Smooth Muscle. European Journal of Pharmacology, 762, 89-95.
[32] Rapp, J.P. (1981) Aortic Responses to Vanadate: Independence from (Na,K)-ATPase and Comparison of Dahl Salt-Sensitive and Salt-Resistant Rats. Hypertension, 3, I168-1172.
[33] Sanchez-Ferrer, C.F., Marin, J., Lluch, M., Valverde, A. and Salaices, M. (1988) Actions of Vanadate on Vascular Tension and Sodium Pump Activity in Cat Isolated Cerebral and Femoral Arteries. British Journal of Pharmacology, 93, 53-60.
[34] Fox, A.A., Borchard, U. and Neumann, M. (1983) Effects of Vanadate on Isolated Vascular Tissue: Biochemical and Functional Investigations. Journal of Cardiovascular Pharmacology, 5, 309-316.
[35] Shimada, T., Shimamura, K. and Sunano, S. (1986) Effects of Sodium Vanadate on Various Types of Vascular Smooth Muscles. Journal of Vascular Research, 23, 113-124.
[36] Spurrell, B.E., Murphy, T.V. and Hill, M.A. (2000) Tyrosine Phosphorylation Modulates Arteriolar Tone but Is Not Fundamental to Myogenic Response. The American Journal of Physiology—Heart and Circulatory Physiology, 278, H373-H382.
[37] Masui, H. and Wakabayashi, I. (2000) Tyrosine Phosphorylation Increases Ca2+ Sensitivity of Vascular Smooth Muscle Contraction. Life Sciences, 68, 363-372.
[38] Murphy, T.V., Spurrell, B.E. and Hill, M.A. (2002) Mechanisms Underlying Pervanadate-Induced Contraction of Rat Cremaster Muscle Arterioles. European Journal of Pharmacology, 442, 107-114.
[39] Voldborg, B.R., Damstrup, L., Spang-Thomsen, M. and Poulsen, H.S. (1997) Epidermal Growth Factor Receptor (EGFR) and EGFR Mutations, Function and Possible Role in Clinical Trials. Annals of Oncology, 8, 1197-1206.
[40] Biscardi, J.S., Maa, M.C., Tice, D.A., Cox, M.E., Leu, T.H. and Parsons, S.J. (1999) C-Src-Mediated Phosphorylation of the Epidermal Growth Factor Receptor on Tyr845 and Tyr1101 Is Associated with Modulation of Receptor Function. The Journal of Biological Chemistry, 274, 8335-8343.
[41] Sato, K., Sato, A., Aoto, M. and Fukami, Y. (1995) C-Src Phosphorylates Epidermal Growth Factor Receptor on Tyrosine 845. Biochemical and Biophysical Research Communications, 215, 1078-1087.
[42] Pai, R., Soreghan, B., Szabo, I.L., Pavelka, M., Baatar, D. and Tarnawski, A.S. (2002) Prostaglandin E2 Transactivates EGF Receptor: A Novel Mechanism for Promoting Colon Cancer Growth and Gastrointestinal Hypertrophy. Nature Medicine, 8, 289-293.
[43] Tice, D.A., Biscardi, J.S., Nickles, A.L. and Parsons, S.J. (1999) Mechanism of Biological Synergy between Cellular Src and Epidermal Growth Factor Receptor. Proceedings of the National Academy of Sciences of the United States of America, 96, 1415-1420.
[44] Haskell, M.D., Slack, J.K., Parsons, J.T. and Parsons, S.J. (2001) C-Src Tyrosine Phosphorylation of Epidermal Growth Factor Receptor, P190 RhoGAP, and Focal Adhesion Kinase Regulates Diverse Cellular Processes. Chemical Reviews, 101, 2425-2440.
[45] Cowan, K.J. and Storey, K.B. (2003) Mitogen-Activated Protein Kinases: New Signaling Pathways Functioning in Cellular Responses to Environmental Stress. Journal of Experimental Biology, 206, 1107-1115.
[46] Zhang, Y., Wang, L.Y., Zhang, M.M., Jin, M.L., Bai, C.X. and Wang, X.D. (2012) Potential Mechanism of Interleukin-8 Production from Lung Cancer Cells: An Involvement of EGF-EGFR-PI3K-Akt-Erk Pathway. Journal of Cellular Physiology, 227, 35-43.
[47] Florian, J.A. and Watts, S.W. (1999) Epidermal Growth Factor: A Potent Vasoconstrictor in Experimental Hypertension. American Journal of Physiology, 276, H976-H983.
[48] Northcott, C., Florian, J.A., Dorrance, A. and Watts, S.W. (2001) Arterial Epidermal Growth Factor Receptor Expression in Deoxycorticosterone Acetate-Salt Hypertension. Hypertension, 38, 1337-1341.
[49] Kim, J., Lee, C.K., Park, H.J., Kim, H.J., So, H.H., Lee, K.S., Lee, H.M., Roh, H.Y., Choi, W.S., Park, T.K. and Kim, B. (2006) Epidermal Growth Factor Induces Vasoconstriction through the Phosphatidylinositol 3-Kinase-Mediated Mitogen-Activated Protein Kinase Pathway in Hypertensive Rats. Journal of Pharmacological Sciences, 101, 135-143.
[50] Li, Y., Levesque, L.O. and Anand-Srivastava, M.B. (2010) Epidermal Growth Factor Receptor Transactivation by Endogenous Vasoactive Peptides Contributes to Hyperproliferation of Vascular Smooth Muscle Cells of SHR. AJP: Heart and Circulatory Physiology, 299, H1959-H1967.
[51] Sandoval, Y.H., Li, Y. and Anand-Srivastava, M.B. (2011) Transactivation of Epidermal Growth Factor Receptor by Enhanced Levels of Endogenous Angiotensin II Contributes to the Overexpression of Gialpha Proteins in Vascular Smooth Muscle Cells from SHR. Cellular Signalling, 23, 1716-1726.
[52] Touyz, R.M., Wu, X.H., He, G., Salomon, S. and Schiffrin, E.L. (2002) Increased Angiotensin II-Mediated Src Signaling via Epidermal Growth Factor Receptor Transactivation Is Associated with Decreased C-Terminal Src Kinase Activity in Vascular Smooth Muscle Cells from Spontaneously Hypertensive Rats. Hypertension, 39, 479-485.

Copyright © 2022 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.